Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dimenhydrinate→

Dimenhydrinate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
523-87-5
Molecular formula
C24H28ClN5O3
Molecular weight
470 g/mol
Drug class
First-generation H1 antihistaminediphenhydramine–8-chlorotheophylline salt complex
Mechanism of action
The antihistamine component diphenhydramine antagonises central H1 receptors and has anticholinergic activity, reducing vestibular stimulation and emetic signalling. 8-Chlorotheophylline is included to reduce sedative effects in some formulations.
Indications / reported uses
  • Prevention and treatment of motion sickness
  • Symptomatic relief of nausea, vomiting and vertigo associated with vestibular disorders; route and age limits depend on the product label

Sources: US DailyMed — Dimenhydrinate products · NHS — Motion sickness medicines · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dimenhydrinate Environmental Risk Assessment (ERA) (the Dimenhydrinate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.